Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
Pfisterer J, Du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F. Pfisterer J, et al. Among authors: schmalfeldt b. Int J Gynecol Cancer. 2009 Jan;19(1):109-15. doi: 10.1111/IGC.0b013e3181991a7c. Int J Gynecol Cancer. 2009. PMID: 19258951 Clinical Trial.
Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H. Kuhn W, et al. Among authors: schmalfeldt b. Cancer. 2001 Nov 15;92(10):2585-91. doi: 10.1002/1097-0142(20011115)92:10<2585::aid-cncr1611>3.0.co;2-#. Cancer. 2001. PMID: 11745193 Clinical Trial.
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, Staehle A, Jackisch C, Lueck HJ, Schroeder W, Burges A, Olbricht S, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). du Bois A, et al. Among authors: schmalfeldt b. Gynecol Oncol. 2005 Feb;96(2):444-51. doi: 10.1016/j.ygyno.2004.10.020. Gynecol Oncol. 2005. PMID: 15661234 Clinical Trial.
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. du Bois A, et al. Among authors: schmalfeldt b. Ann Oncol. 2006 Jan;17(1):93-6. doi: 10.1093/annonc/mdj032. Epub 2005 Nov 9. Ann Oncol. 2006. PMID: 16282248 Free article. Clinical Trial.
[Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO].
Schmalfeldt B, du Bois A, Burges A, Emons G, Fink D, Gropp M, Hasenburg A, Jäger W, Kimmig R, Kiechle M, Kommoss F, Kreienberg R, Kuhn W, Lück HJ, Meier W, Münstedt K, Ortmann O, Pfisterer J, Richter B, Runnebaum I, Schröder W, Sehouli J, Tanner B, Wagner U, Weis J. Schmalfeldt B, et al. Zentralbl Gynakol. 2006 Feb;128(1):11-7. doi: 10.1055/s-2006-921345. Zentralbl Gynakol. 2006. PMID: 16450281 German.
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group. Harter P, et al. Among authors: schmalfeldt b. Ann Surg Oncol. 2006 Dec;13(12):1702-10. doi: 10.1245/s10434-006-9058-0. Ann Surg Oncol. 2006. PMID: 17009163 Clinical Trial.
Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?
du Bois A, Schmalfeldt B, Meier W, Sehouli J, Pfisterer J; Arbeitsgemeinschaft Gynaekologische Onkologie [AGO] Kommission OVAR; AGO Study Group Ovarian Cancer [AGO-OVAR]; Norddeutsche Gesellschaft Fuer Gynaekologische Onkologie [NOGGO]. du Bois A, et al. Among authors: schmalfeldt b. Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1756-60. doi: 10.1111/j.1525-1438.2006.00712.x. Int J Gynecol Cancer. 2006. PMID: 17009967 Review.
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Lück HJ, Sehouli J, Gropp M, Stähle A, Schmalfeldt B, Meier W, Jackisch C; AGO Ovarian Cancer Study Group. Wagner U, et al. Among authors: schmalfeldt b. Gynecol Oncol. 2007 Apr;105(1):132-7. doi: 10.1016/j.ygyno.2006.10.053. Epub 2006 Dec 11. Gynecol Oncol. 2007. PMID: 17161453 Clinical Trial.
192 results